Group 1 - The company plans to repurchase shares through centralized bidding, with a maximum price of 9.82 CNY per share and a total repurchase amount between 25 million CNY and 50 million CNY [2] - As of October 31, 2025, the company has repurchased a total of 1,101,600 shares, accounting for 0.07% of the total share capital, with a maximum purchase price of 6.10 CNY and a minimum of 5.97 CNY, totaling 6,650,658 CNY spent [3] - The repurchase plan complies with relevant laws and regulations [4] Group 2 - The company will make repurchase decisions based on market conditions and will fulfill information disclosure obligations in a timely manner [5]

Core Viewpoint - The company, Beijing Eight Billion Space Liquid Crystal Technology Co., Ltd., has initiated a share repurchase program to enhance shareholder value and potentially support employee stock ownership plans [1][2]. Summary by Sections 1. Basic Information on Share Repurchase - On May 16, 2025, the company’s board approved a share repurchase plan using its own funds and a special loan of up to 70 million RMB from Shanghai Pudong Development Bank [1] - The repurchase will target a maximum price of 40 RMB per share, with a total repurchase amount between 50 million RMB and 100 million RMB [1] - The repurchase period is set for 12 months from the board's approval date [1] 2. Progress of Share Repurchase - As of October 31, 2025, the company has repurchased a total of 477,000 shares, representing 0.35% of its total share capital of 134,481,546 shares [2] - The highest price paid for the repurchased shares was 28.20 RMB, while the lowest was 27.69 RMB, with a total expenditure of approximately 13.37 million RMB (excluding transaction fees) [2] - The repurchase activities are in compliance with relevant laws and the company's repurchase plan [2] 3. Other Matters - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [3]

Core Viewpoint - The company has initiated a share buyback program to utilize its own funds for repurchasing shares, aiming to enhance shareholder value and support employee incentive plans [2][3]. Group 1: Share Buyback Basic Information - On September 24, 2025, the company’s board approved a plan to repurchase shares through centralized bidding, with a maximum buyback price set at 42 RMB per share [2]. - The total funds allocated for the buyback will range from 30 million RMB to 50 million RMB, with a buyback period of 12 months from the board's approval date [2]. Group 2: Progress of Share Buyback - As of October 2025, the company has repurchased a total of 370,637 shares, representing 0.11% of the total share capital of 330 million shares [3]. - The highest price paid for the repurchased shares was 27.18 RMB per share, while the lowest was 26.79 RMB per share, with a total expenditure of approximately 9,999,703.49 RMB (excluding transaction fees) [3]. Group 3: Compliance and Future Actions - The share buyback is in compliance with relevant laws and regulations, and the company will continue to make buyback decisions based on market conditions while fulfilling disclosure obligations [4][5].

Group 1 - The company has approved a share repurchase plan using its own and raised funds, with a total repurchase amount between RMB 50 million and RMB 100 million, and a maximum repurchase price of RMB 173.00 per share [2] - The repurchase period is set to not exceed 12 months from the date of the shareholder meeting that approved the plan [2] - As of October 31, 2025, the company has repurchased 71,181 shares, accounting for 0.0201% of the total share capital, with a total expenditure of RMB 9,901,371.38 [3] Group 2 - The repurchase is in compliance with relevant laws and regulations, as well as the company's own repurchase plan [4] - The company will make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [5]

Core Points - The company has approved a share repurchase plan using excess funds from its initial public offering, with a maximum repurchase price of RMB 170 per share and a total repurchase amount between RMB 100 million and RMB 200 million [1][7] - As of October 31, 2025, the company has not yet repurchased any shares [2] - The company will adhere to relevant regulations and guidelines during the repurchase period and will disclose information in a timely manner [4][3] Shareholder Information - The company has announced the names, shareholdings, and shareholding ratios of the top ten shareholders and the top ten unrestricted shareholders as of the board meeting on October 29, 2025 [6][7]

Group 1 - The company has approved a share repurchase plan using a combination of bank loans and self-raised funds, with a total amount between RMB 200 million and RMB 400 million, and a maximum repurchase price of RMB 39.52 per share [1] - The repurchase period is set for 12 months from the date of board approval, which was on June 17, 2025 [1] - The repurchased shares will be used for employee stock ownership plans and/or equity incentives, or for converting convertible bonds issued by the company [1] Group 2 - As of October 31, 2025, the company has repurchased a total of 1,594,574 shares, accounting for 0.5685% of the total share capital, with a total expenditure of RMB 39,994,363.09 [2] - The highest repurchase price recorded was RMB 26.06 per share, while the lowest was RMB 24.34 per share [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [2]

Group 1 - The company has approved a share repurchase plan with a total fund of no less than RMB 60 million and no more than RMB 120 million, to be executed within 12 months from the board's approval date [1][3] - The maximum repurchase price was adjusted from RMB 17 per share to RMB 11.93 per share due to corporate actions such as dividend distribution and capital reserve conversion [1][3] - As of the end of October 2025, the company has repurchased a total of 8,842,464 shares, accounting for 2.8639% of the total share capital, with a total expenditure of approximately RMB 100.09 million [3][4] Group 2 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [5]

Core Viewpoint - The company, 博瑞生物医药 (Suzhou) Co., Ltd., has initiated a share repurchase program to utilize its own funds for buying back shares, which will be used for employee stock ownership plans or equity incentives in the future [1][3]. Summary by Sections 1. Share Repurchase Basic Information - On September 26, 2025, the company’s board approved a plan to repurchase shares through centralized bidding, with a maximum repurchase price of RMB 139.77 per share and a total fund allocation between RMB 10 million and RMB 20 million [1]. 2. Progress of Share Repurchase - As of October 31, 2025, the company has repurchased a total of 55,880 shares, representing 0.0132% of the total share capital of 423,102,473 shares. The highest and lowest prices for the repurchased shares were RMB 54.28 and RMB 52.96, respectively, with a total expenditure of RMB 2,993,933.37 (excluding transaction fees) [3]. 3. Other Matters - The company will adhere to relevant regulations during the repurchase period and will disclose information regarding the progress of the share repurchase in a timely manner [5].

Core Viewpoint - Sichuan Tianwei Food Group Co., Ltd. has initiated a share repurchase plan to enhance employee stock ownership and equity incentive programs, with a total repurchase amount estimated between 18 million to 36 million yuan [1] Group 1: Share Repurchase Basic Information - The company plans to repurchase between 2,000,000 and 4,000,000 shares using its own funds through centralized bidding, with the repurchase period from April 29, 2025, to April 28, 2026 [1] - The repurchase is intended for future implementation of employee stock ownership plans or equity incentive plans [1] Group 2: Progress of Share Repurchase - In October 2025, the company repurchased 229,300 shares, accounting for approximately 0.0215% of the total share capital, with a total transaction amount of 2,739,586 yuan [2] - As of October 31, 2025, the cumulative repurchased shares reached 1,319,420, representing 0.1239% of the total share capital, with a total payment of 15,514,627.20 yuan [2] Group 3: Compliance and Risk Management - The share repurchase complies with relevant laws and regulations [3] - The company collaborates with securities firms to utilize off-market derivative tools such as yield swaps and over-the-counter options to manage repurchase costs and mitigate risks associated with stock price fluctuations [4][5] - Risk management measures include matching derivative transactions with the share repurchase plan and controlling the scale of derivative trading [5]

Group 1 - Jiangsu Hengrui Medicine Co., Ltd. announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd.'s HRS-5965 capsules have been proposed for inclusion in the priority review list by the National Medical Products Administration (NMPA) [1][2] - HRS-5965 capsules are intended for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1][2] - PNH is a rare acquired hemolytic disease characterized by the lack of CD55 and CD59, leading to complement-mediated intravascular hemolysis, and has been included in the national rare disease directory [2] Group 2 - The company has received approval from the NMPA for the clinical trial of Ruvelimab tablets, which are second-generation androgen receptor (AR) inhibitors, with a stronger AR inhibition effect compared to first-generation inhibitors [7][8] - Ruvelimab tablets were approved for the treatment of high-burden metastatic hormone-sensitive prostate cancer (mHSPC) in 2022, and similar products are projected to have a combined global sales of approximately $11.037 billion in 2024 [8] - The company has invested approximately 693.09 million yuan in the development of Ruvelimab tablets [8] Group 3 - The company has initiated a share repurchase program, with a total repurchase amount between 1 billion and 2 billion yuan, at a maximum price of 90.85 yuan per share [11][12] - As of October 31, 2025, the company has repurchased a total of 7.9188 million shares, accounting for 0.12% of the total share capital, with a total expenditure of approximately 535.43 million yuan [13] - The repurchase is in accordance with relevant laws and regulations and the company's established repurchase plan [14]